Skip to main content

Pfizer Ends Testing of Obesity Pill, Danuglipron, After Possible Liver Injury

By I. Edwards HealthDay Reporter

Medically reviewed by Carmen Pope, BPharm. Last updated on April 15, 2025.

via HealthDay

TUESDAY, April 15, 2025 — Pfizer has stopped developing a once-daily pill to treat obesity after a person in a clinical trial showed signs of a possible liver injury.

The company said the injury went away after the person stopped taking the drug, called danuglipron, The Associated Press reported.

The pill was in early testing to help determine the best dose, according to a Pfizer spokeswoman.

The company had planned to move the drug into late-stage trials, typically the final step before review by the U.S. Food and Drug Administration (FDA).

Pfizer will now stop all testing of danuglipron, including its use with other drugs for obesity treatment. However, the company said it still plans to work on other obesity treatments that are in earlier stages of research.

Obesity drugs have become a major focus for pharmaceutical companies. Injectable treatments like Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy have brought in billions in revenue. Zepbound earned nearly $5 billion in 2024 alone, The Associated Press reported.

But these drugs must be injected, which some folks don't want to do.

As a result, drugmakers have been racing to develop pill versions. Lilly expects to release new data this year on two oral obesity drugs it is studying.

While demand for these treatments is high, access has been an issue. Some patients face insurance issues or high out-of-pocket costs.

Even with recent price cuts, many of these medications still cost hundreds of dollars per month.

Pfizer had already stopped testing of a twice-daily version of danuglipron in late 2023 after more than half the people in a trial stopped taking it.

Sources

  • The Associated Press, April 14, 2025

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Posted April 2025

Read this next

First Malaria Drug Approved for Newborns and Small Babies, Coartem Baby

WEDNESDAY, July 9, 2025 — A new malaria treatment has been approved for newborns and infants under 11 pounds, filling a major gap in care for some of the most vulnerable...

Insured? You're More Likely To Survive Cancer Through Immunotherapy Treatment

WEDNESDAY, July 9, 2025 — Powerful new immunotherapies are offering fresh hope for patients with many different types of cancer. Unfortunately, that hope doesn’t...

American Academy of Pediatrics Sues HHS Over Vaccine Policy

TUESDAY, July 8, 2025 -- The American Academy of Pediatrics is suing the U.S. Department of Health and Human Services because of its recent decisions regarding vaccines for...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.